Branched stent grafts for bulges in the body's main artery
Tests branched stent-graft devices for aortic aneurysms in adults.
Key facts
- Who runs it
- Baptist Health South Florida
- Where
- Boca Raton, United StatesSee the site
- Trial code
- Registry title
- Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
- Status
- Recruiting
- People taking part
- 235 people, planned
- Started
- 25 Jan 2012
- Expected to end
- Jan 2032
- Type of study
- Interventional, 2 groups
- Treatments tested
- Zenith® t-Branch
- Terumo Arch Branch
- Record updated
- 15 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a large or growing aneurysm (bulge), ulcer or long-lasting tear of the aorta, the body's main artery. They will be treated with a branched stent-graft placed through the blood vessels.
- Age
- 18 years and older.
- Sex
- All sexes.
- Disease stage
- Zenith t-Branch group: aneurysm in the chest-belly aorta ≥55mm wide in men or ≥50mm in women, growth ≥0.5 cm per year, ulcer ≥20mm deep, chronic type B tear ≥50mm, or any size with symptoms. Terumo Arch Branch group: aneurysm in the upper aorta or arch ≥55 mm, or > 50 mm with growth ≥5 mm in 6 months, ulcer ≥20 mm deep, or chronic tear ≥50mm. These people must also be at high risk for open surgery, for example age >85 years, severe lung or kidney disease, or a past chest-bone opening operation.
- Earlier treatment
- Terumo Arch Branch group: cannot join after a mechanical aortic valve replacement or a TAVR (valve replaced through a catheter). A past aortic repair can count as a high surgery risk.
Main reasons for not taking part
- Expected to live less than 1 year, or untreatable cancer.
- Pregnant, breastfeeding, or planning pregnancy within 60 months.
- Refusing blood products, or uncontrolled body-wide infection.
- Severe allergy to contrast dye or to the device materials.
- Aorta shape or vessel size that does not allow the device to be placed; infection-caused aneurysm.
The registry criteria, word for word
Show all 63 criteriaShow less
Who can take part
- The patient must have one of the following:
- Degenerative, atherosclerotic thoracoabdominal, suprarenal and juxtarenal aortic aneurysms (fusiform or saccular):≥55mm in diameter in a male or ≥50mm in diameter in a female, or
- Thoracoabdominal aortic aneurysm with a history of growth ≥0.5 cm per year, or
- Penetrating ulcers: ≥20mm in depth or
- Chronic type B aortic dissections: ≥50mm total aortic diameter or
- Symptomatic pathology (aneurysm, ulcer or chronic dissection) of any size; Additional criteria for LP material
- Iliofemoral access vessels <8mm or with significant atherosclerotic occlusive disease that would require an iliac conduit as determined by the Principle Investigator
- The subject must have one of the following:
- Degenerative, atherosclerotic aneurysm involving the ascending aorta, aortic arch or proximal descending aorta ≥55 mm in diameter or > 50 mm with a history of growth ≥5 mm in the last 6 months, or
- Penetrating ulcers: ≥20 mm in depth, or
- Chronic aortic dissections: ≥50mm total aortic diameter. AND Prohibitive or high-risk for standard open surgical repair, defined as having one or more of the following pre-existing conditions; Age >85 years old; Prior median sternotomy (for any reason); Prior open or endovascular thoracic aortic repair; Severe aortic calcification; Severe occlusive disease of one or more arch vessels; Moderate-severe COPD (FEV1 <80% predicted); Severe CKD (Stage 3 or greater, eGFR <60 mL/min); LV dysfunction; Chronic steroid or immunosuppressive use; History of increased risk of bleeding; Neurocognitive deficits that may significantly impact postoperative rehabilitation; Musculoskeletal conditions that may significantly impact postoperative rehabilitation
Who cannot take part
- Prior mechanical aortic valve replacement (not bioprosthetic)
- Uncontrolled systemic infection
- Untreatable malignancy
- Known allergy(ies) to device materials; Anatomic Criteria
- Pending cardiac surgery
- Untreatable severe, symptomatic coronary or valvular disease
- History of TAVR (Transcatheter Aortic Valve Replacement)
- Uncontrolled systemic infection
- Untreatable malignancy with <1 year expected survival
- Known allergy(ies) to device materials. (i.e. polyester, nitinol); Anatomic Criteria
- Age <18 years
- Age <18 years
- General Criteria
- Life-expectancy less than 12 months
- Refusal to receive blood products
- Pregnant or breastfeeding or planning on becoming pregnant within 60 months
- Unwilling to comply with the follow-up schedule
- Inability or refusal to give informed consent by subject and/or Legally Authorized Representative (LAR); should one be utilized; Medical Criteria
- Uncontrollable anaphylaxis to iodinated contrast
- Any pathology of mycotic origin
- Aortic fistulous communication with non-vascular structure (e.g. esophagus, bronchial)
- Inability to insert the Zenith® t-Branch device through iliofemoral approach
- Proximal and distal neck angle less than 90 degrees relative to the long axis of the aneurysm
- Proximal landing zone length <25mm to allow secure fixation and seal
- Proximal landing zone diameter of <24mm or >42mm
- Distal landing zone length <25mm in the abdominal aorta or <20mm in the iliac arteries
- Distal landing zone diameter of <14mm or >30mm in the abdominal aorta, or <7mm or >28mm in the iliac arteries; Terumo Arch Branch Eligibility Criteria
- General Criteria
- Life expectancy <1 year
- Refusal to receive blood products
- Pregnant, breastfeeding, or planning to become pregnant within 60 months
- Unwilling to comply with the follow-up schedule
- Inability or refusal to give informed consent by subject and/or Legally Authorized Representative (LAR); should one be utilized
- Willingness to travel, if needed, to participate in a manufacturer-sponsored clinical trial at another institution; Medical Criteria
- Severe, calcific aortic valvular stenosis
- Uncontrollable anaphylaxis to iodinated contrast
- Any pathology of mycotic origin
- Aortic fistulous communication with non-vascular structure (e.g. esophagus, bronchial)
- Acute (<2 weeks) aortic dissection
- Type A dissection
- Symptomatic or ruptured pathology
- Anatomy suitable for repair using commercially-available endograft
- Inability to insert the Arch Branch endograft through an iliofemoral approach
- Untreated, known extracranial carotid stenosis >80%
- Ascending aortic angulation with radius of curvature <15mm in the intended landing zone
- Proximal aortic landing zone length <25 mm
- Proximal aortic landing zone diameter of >43mm or <28 mm
- Distal aortic landing zone diameter <20 mm
- Total length along the outer curve from the distal coronary to the proximal edge of the brachiocephalic trunk <70mm
- Target arch vessels:
- Distal branch landing zone dimensions: I. Brachiocephalic trunk (innominate artery, BCT): Diameter >24 mm or <6 mm, length <15 mm. ii. Common carotid artery: Diameter <6 mm, length <25mm. iii. Subclavian artery: Diameter <6 mm, length <25mm
Other criteria
- Zenith t-Branch Eligibility Criteria:
Where in United States
- Baptist Health South Florida|Boca Raton Regional Hospital (BRRH)Boca Raton, United StatesContact: Lisamarie Kernicky, RN;BSN;CCRCTaking people
About the trial
What the trial wants to find out
Zenith t-Branch Study Cohort: The purpose of this study is to collect information on the Cook Zenith t-Branch endovascular stent-graft system and the Terumo Arch Branch for the treatment of aortic aneurysms.
Read full original descriptionShow less
Terumo Arch Branch Study Cohort: The purpose of this additional study arm to the current IDE clinical trial is to collect a priori information on the Terumo Arch Branch Endograft for the treatment of proximal thoracic aortic pathologies that cannot be treated with conventional thoracic endografts.
The 2 groups in the trial
- Single Treatment Arm-Zenith t-Branch CohortTreatment being tested
Zenith t-Branch Cohort:Those subjects eligible for enrollment will receive endovascular treatment with the investigational Zenith t-Branch Endovascular Graft.
Treatment: Zenith® t-Branch
- Single Treatment Arm-Terumo Arch Branch CohortTreatment being tested
Terumo Arch Branch Cohort:Those subjects eligible for enrollment will receive endovascular treatment with the investigational Terumo Arch Branch Endovascular Graft.
Treatment: Terumo Arch Branch
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
- Plain-language title
- Branched stent grafts for bulges in the body's main arteryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Publications
- Trends and outcomes over time with fenestrated and branched endovascular aortic repair in the United States Aortic Research Consortium.Journal of vascular surgery, 2025
- Severity of acute kidney injury is associated with decreased survival after fenestrated and branched endovascular aortic aneurysm repair.Journal of vascular surgery, 2023
- Record updated
- 15 June 2026